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Left Ventricular Hypertrophy Is Associated With Increased Infarct Size
and Decreased Myocardial Salvage in Patients With ST-Segment
Elevation Myocardial Infarction Undergoing Primary Percutaneous
Coronary Intervention
Lars Nepper-Christensen, MD; Jacob Lønborg, MD, PhD, DMSc; Kiril Aleksov Ahtarovski, MD, PhD; Dan Eik Høfsten, MD, PhD; Kasper Kyhl,
MD, PhD; Adam Ali Ghotbi, MD; Mikkel Malby Schoos, MD, PhD; Christoffer G€oransson, MD; Litten Bertelsen, MD; Lars Køber, MD, PhD,
DMSc; Steffen Helqvist, MD, DMSc; Frants Pedersen, MD, PhD; Kari Sa€unamaki, MD, DMSc; Erik Jørgensen, MD; Henning Kelbæk, MD,
DMSc; Lene Holmvang, MD, DMSc; Niels Vejlstrup, MD, PhD; Thomas Engstrøm, MD, PhD, DMSc
Background-—Approximately one third of patients with ST-segment elevation myocardial infarction (STEMI) have left
ventricular hypertrophy (LVH), which is associated with impaired outcome. However, the causal association between LVH and
outcome in STEMI is unknown. We evaluated the association between LVH and: myocardial infarct size, area at risk,
myocardial salvage, microvascular obstruction, left ventricular (LV) function (all determined by cardiac magnetic resonance
[CMR]), and all-cause mortality and readmission for heart failure in STEMI patients treated with primary percutaneous
coronary intervention.
Methods and Results-—In this substudy of the DANAMI-3 trial, 764 patients underwent CMR. LVH was deﬁned by CMR and
considered present if LV mass exceeded 77 (men) and 67 g/m2 (women). One hundred seventy-eight patients (24%) had LVH. LVH
was associated with a larger ﬁnal infarct size (15% [interquartile range {IQR}, 10–21] vs 9% [IQR, 3–17]; P<0.001) and smaller ﬁnal
myocardial salvage index (0.6 [IQR, 0.5–0.7] vs 0.7 [IQR, 0.5–0.9]; P<0.001). The LVH group had a higher incidence of
microvascular obstruction (66% vs 45%; P<0.001) and lower ﬁnal LV ejection fraction (LVEF; 53% [IQR, 47–60] vs 61% [IQR, 55–65];
P<0.001). In a Cox regression analysis, LVH was associated with a higher risk of all-cause mortality and readmission for heart
failure (hazard ratio 2.59 [95% CI, 1.38–4.90], P=0.003). The results remained statistically signiﬁcant in multivariable models.
Conclusions-—LVH is independently associated with larger infarct size, less myocardial salvage, higher incidence of microvascular
obstruction, lower LVEF, and a higher risk of all-cause mortality and incidence of heart failure in STEMI patients treated with
primary percutaneous coronary intervention.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01435408. ( J Am Heart Assoc. 2017;6:
e004823. DOI: 10.1161/JAHA.116.004823.)
Key Words: cardiac magnetic resonance imaging • left ventricular hypertrophy • myocardial infarction • primary percutaneous
coronary intervention • ST-segment elevation myocardial infarction
S everal studies have shown that increased left ventricular(LV) mass, known as LV hypertrophy (LVH), is an
independent predictor of cardiovascular events and death.1–3
LVH increases the risk of myocardial infarction (MI) and it
is prognostic post-MI.4,5 Despite the presence of LVH in
approximately one third of patients with MI,6 the causal
association between LVH and impaired outcome in patients
with ST-segment elevation myocardial infarction (STEMI)
remains unknown. Experimental studies have demonstrated
that animals with LVH have less myocardial salvage and larger
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infarct size following ischemia-reperfusion.7–10 However, the
impact of LVH on myocardial infarct size has only sparsely
been studied in STEMI patients,11 and data regarding the
relationship between LVH and microvascular obstruction
(MVO), area at risk or myocardial salvage are to the best of
our knowledge non-existent.
LVH is deﬁned as increased LV mass indexed by body
surface area (BSA)12 and is divided into eccentric and
concentric hypertrophy.13 The utility of this subclassiﬁcation
has previously been demonstrated by signiﬁcant differences
in outcomes between patients with eccentric and concentric
LVH.1,5,6 However, there are no data regarding the relation-
ship between these subgroups and the extent of post-MI
myocardial damage.
Cardiovascular magnetic resonance (CMR) provides an
accurate method for in vivo assessment of infarct size,14,15
area at risk,16–19 myocardial salvage index,20,21 MVO,22 LV
mass, and LV ejection fraction (LVEF).23
Thus, in the present study we evaluated the association
between LVH and myocardial infarct size, area at risk,
myocardial salvage, MVO, and LV function in STEMI patients.
Moreover, we investigated the association between LVH and
all-cause mortality and hospitalization for heart failure.
Methods
Study Population
The present study is a substudy of the DANAMI-3 trial
(www.clinicaltrials.gov; identiﬁer: NCT01435408) that has
been previously described.24 In brief, DANAMI-3 comprises
3 randomized, multicenter trials evaluating ischemic post-
conditioning (DANAMI3-iPOST), deferred stenting (DANAMI3-
DEFER), and complete fractional ﬂow reserve guided
revascularization (DANAMI3-PRIMULTI) in STEMI patients.
Only patients included at 1 center, Rigshospitalet, Copen-
hagen University Hospital, were considered for inclusion in
the CMR substudy. Patients were eligible if they were aged
≥18 years and had acute onset of chest pain of <12 hours’
duration and ST-segment elevation ≥0.1 mV in ≥2 contigu-
ous leads, or documented newly developed left bundle
branch block. Patients were excluded from the CMR
substudy if they had contraindications for CMR, such as
claustrophobia, severely reduced kidney function, metal
implants, arrhythmia, previous infarction in the current
infarct-related artery, or were clinically unstable. The clinical
endpoint of all-cause mortality and hospitalization for heart
failure was chosen a priori.25 All-cause mortality and
hospitalization for heart failure were identiﬁed from the
National Danish Heart Registry and validated using hospital
records; all events were validated by an independent events
committee.
The study protocol was approved by a central ethics
committee in Copenhagen, and the trial program was
undertaken in accord with the Declaration of Helsinki. Ethical
approval was received, according to local regulations, and
data were gathered electronically and stored at the Clinical
Trial Unit of Rigshospitalet. All patients provided written
informed consent.
CMR and Image Analysis
All patients without contraindications for CMR were offered an
initial scan during the index admission (median of 1 day
[interquartile range {IQR}, 1–1] following primary percuta-
neous coronary intervention [primary PCI]) to assess mass,
area at risk, acute infarct size, cardiac function, and MVO.
A second scan was performed 3 months later (median of
91 days [IQR, 88–96]) to assess ﬁnal infarct size and cardiac
function. CMR was performed using a 1.5 Tesla scanner
(Avanto [admission] and Espree [follow-up] scanner; Siemens,
Erlangen, Germany) using a 6-channel body array coil.
Scout images and electrocardiographic (ECG) gated
breath-hold steady-state free-precession images in 2-, 4-,
and 3-chamber views were performed to set up short-axis
plane imaging. Area at risk was assessed as edema on the
initial scan using a T2-weighted short tau inversion-recovery
sequence.21,26 LV volume, function, and mass were measured
on both CMR examinations using a standard ECG-triggered
balanced steady-state free-precession cine sequence. Acute
and ﬁnal infarct sizes were evaluated on the initial and second
CMR examination, respectively, using delayed contrast-
enhancement CMR.21 Infarct images were obtained 10 min-
utes after intravenous injection of 0.1 mmol/kg body weight
of gadolinium-based contrast (Gadovist; Bayer Schering,
Berlin, Germany) using an ECG-triggered inversion-recovery
sequence. The inversion time was adjusted to null the signal
from the normal myocardium. All short-axis images were
obtained from the atrioventricular plane to the apex with 8-
mm-thick slices and no interslice gap to cover the entire LV.
All images were analyzed by an independent observer
blinded to all clinical data, using CVI42 (Circle Cardiovascular
Imaging Inc., Calgary, Alberta, Canada). All analyses were
reviewed and ﬁnalized by a second observer. The epicardial
and endocardial contours were manually traced on all images,
incorporating the papillary muscles as part of the LV cavity.
LV volumes, LVEF, and mass were calculated on the short-axis
cine images. End-diastole and end-systole were identiﬁed as
the largest and smallest volume, respectively, according to
blood pool area. Area at risk was deﬁned as the hyperintense
area on T2-weighted images. A myocardial area was reported
as hyperintense when the signal intensity was >2 SDs of the
mean signal intensity of normal reference myocardium. Using
CVI42 (Circle Cardiovascular Imaging Inc.), an area of at least
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10 pixels in the remote normal myocardium was used as a
reference value for the normal signal intensity. This area was
visually identiﬁed in each short-axis slice. All areas with signal
intensity >2 SDs of the normal value were automatically
measured. Hyperintensive areas scattered throughout the
remote myocardium were manually excluded from the area at
risk, just as hypointensive areas within the area at risk were
manually included as part of the area at risk. The area at risk
was expressed in percentages of LV. The infarction was
deﬁned as the hyperenhanced myocardium on the delayed
gadolinium-enhanced short-axis images. A myocardial area
was regarded as hyperenhanced when the signal intensity was
>5 SDs of the mean intensity of normal reference myocar-
dium.27 Using CVI42 (Circle Cardiovascular Imaging Inc.), an
area of at least 10 pixels in the remote normal myocardium
was used as a reference value for the normal signal intensity.
This area was visually identiﬁed in each short-axis slice. All
areas with signal intensity >5 SDs of the normal value were
automatically measured. Hyperenhanced areas scattered
throughout the remote myocardium were manually excluded
from the infarct size, just as nonculprit infarct areas were
excluded. The infarct size was expressed in grams and
percentage of LV mass. Hypointense core areas in the
enhanced myocardium were deﬁned as MVO and manually
included in the total infarct size. MVO was manually measured
in each short-axis image slice. The salvage index was
calculated as (area at riskinfarct size)/area at risk.20
Interobserver reproducibility was assessed in 20 randomly
chosen patients and expressed as mean differencelimits of
agreement: 0.26 g for acute LV mass; 0.54% for acute
LVEF; 0.12% LV for acute infarct size; and 12% LV for area
at risk.
Left Ventricular Hypertrophy
Previous studies have reported different values for the upper
limit of normal LV mass.13,28,29 To address these differences,
CMR data on LV mass and concentricity were obtained from
44 healthy subjects (22 men and 22 women). None of the
healthy subjects had hypertension, diabetes mellitus, or
known previous heart diseases, and there was no statistically
signiﬁcant difference in age between the healthy subjects and
the patients in the substudy group (609 vs 5911 years;
P=0.596). End-diastolic LV mass on the acute CMR was
indexed by BSA and LVH was deﬁned as LV mass exceeding
the upper 95th percentile among healthy subjects. BSA was
calculated using the Du Bois formula.29 In order to stratify
patients with LVH into eccentric and concentric LVH, data
from the healthy subjects were used to calculate sex-speciﬁc
values for LV concentricity0.67 (mass/LV end-diastolic vol-
ume0.67).13 Increased concentricity was deﬁned as concen-
tricity0.67 exceeding the upper 95th percentile. The presence
of LVH and increased concentricity was classiﬁed as concen-
tric LVH. The presence of LVH in absence of increased
concentricity was classiﬁed as eccentric LVH. To minimize the
risk of the CMR readers being aware of the presence or
absence of LVH they were blinded to BSA. Additionally, the
images from the 44 healty subjects were analyzed after CMR
data from the study population were obtained.
Statistical Analysis
Normality of continuous variables was evaluated by his-
tograms. Student t test was performed if the data were
considered normally distributed, and the Mann–Whitney U
test was used otherwise. Categorical variables were com-
pared with the chi-square test or Fisher’s exact test.
Regression analyses were performed to compare the rela-
tionship between area at risk and infarct size, and ANCOVAs
were used to test equality of the regression lines for the
hypertrophic and the normotrophic groups. The effect of LVH
was adjusted for potential confounders in multivariable linear
and logistic regression analyses using any baseline variable
with P≤0.20 for the difference between the groups. Interac-
tion between LVH and any baseline variable used in the
multivariable models were evaluated in an ANCOVA. The
assumptions for general linear models were checked and
deemed valid. The Kaplan–Meier method was used for visual
assessment of time-to-event endpoints. Hazard ratios (HRs)
were calculated using Cox regression analyses. The effect of
LVH was adjusted for potential confounders in a multivariable
Cox regression analysis using any baseline variable with
P≤0.20 for the difference between the groups. The assump-
tions of the proportional hazard were checked and deemed
valid. A 2-sided probability value <0.05 was considered
statistically signiﬁcant. All statistical analyses were performed
with SPSS software (version 23.0; SPSS, Inc., Chicago, IL).
Results
Left Ventricular Hypertrophy
Based on the 44 healthy subjects, LVH was considered
present if LV mass exceeded 77 g/m2 for men and 67 g/m2
for woman. The values for concentricity were ≥5 (men) and
≥4 g/mL0.67 (women).
Study Population
A ﬂow chart of patient inclusion is shown in Figure 1. A total
of 178 patients (24%) had LVH and 579 (76%) had
normotrophic left ventricles. Baseline demographics as well
as angiographic and procedural characteristics of all patients,
stratiﬁed by the presence of LVH, are depicted in Table 1.
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Patients with LVH were more likely to be men, have a higher
body mass index (BMI), higher blood pressures at admission,
higher levels of peak troponins, pre-PCI thrombolysis in
myocardial infarction (TIMI) ﬂow 0/1, ECG-veriﬁed anterior
infarct location, and thus also a higher incidence of infarcts
located to the left anterior descending artery (Table 1).
Additionally, there was a trend towards a higher incidence of
previous MI and longer delays from symptom onset to wire in
patients with LVH. All patients included, with the exception of
4, were followed for 37 months (IQR, 30–47).
Infarct Size and Salvage Index
Patients with LVH had larger area at risk and developed larger
acute and ﬁnal infarct size compared with normotrophic
patients (Table 2). After adjusting for area at risk, a linear
regression analysis showed that the group with LVH had
signiﬁcantly larger acute and ﬁnal infarcts than the nor-
motrophic group (Figures 2 and 3), which indicates that
patients with LVH developed signiﬁcantly larger infarcts for
an equivalent area at risk. There was no interaction between
1620 patients included 
654 with data from acute 
and follow-up CMR
109 with data from acute 
CMR only
47 with data from follow-
up CMR only
130 not considered for 
CMR 
57 CMR protocol not started
44 other 
20 previous AMI/PCI in the IRA 
9 no myocardial infarction
1490 eligible for 
inclusion  
726 lost to acute CMR
153 claustrophobia
153 refusal
130 contraindication
66 unknown
67 discharged before CMR
61 clinically unstable
42 arrhythmia 
33 technical problems   
18 could not cooperate
3 death
764 acute CMR
109 lost to follow-up 
CMR
51 refusal
20 other
20 contraindications
7 death
4 clinical unstable
4 technical problems
3 claustrophobia 
47 follow-up CMR  
without acute CMR
757 with data on acute mass and volume
731 with data on acute infarct size
723 with data on area at risk
701 with data on final mass and volume
697 with data on final infarct size 
620 with data on final salvage index
Figure 1. Flow chart of patient inclusion. AMI indicates acute myocardial infarction; CMR,
cardiac magnetic resonance; IRA, infarct related artery PCI, percutaneous coronary
intervention.
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area at risk and LVH (P=0.120). Furthermore, patients with LVH
had smaller myocardial salvage indices and a higher incidence
of MVO compared with normotrophic patients (Table 2).
Patients with LVH also had lower LVEF both in the acute phase
and at follow-up (Table 2). Adjusting for sex, BMI, hypertension,
systolic and diastolic blood pressure (BT), previous MI,
symptom to wire, anterior infarct location, pre-PCI TIMI ﬂow
0/1, post-PCI TIMI-ﬂow 3, and multivessel disease in multi-
variable linear regression analyses, the difference in infarct
size, myocardial salvage index, and LVEF between the LVH
group and the normotrophic group remained statistically
signiﬁcant (Table 3). Adjusting for the same variables in a
logistic regression analysis, the association between MVO and
LVH also remained statistically signiﬁcant (Table 3).
A combined endpoint of all-cause mortality and readmis-
sion for heart failure occurred in 16 (9%) of the patients with
LVH and in 24 (4%) of the normotrophic patients (HR, 2.59
[95% CI, 1.38–4.90]; P=0.003; Figure 4). This association
remained statistically signiﬁcant in a multivariable Cox
regression analysis, adjusting for sex, BMI, hypertension,
Table 1. Baseline Demographics and Angiographic and Procedural Characteristics
Normal Hypertrophic
P Value(n=579) (n=178)
Age, y 5911 5810 0.457*
Male (%) 450 (78) 153 (86) 0.019
BMI 274 284 0.032*
Diabetes mellitus (%) 43 (7) 13 (7) >0.999
Family history of CAD (%) 281 (49) 89 (50) 0.863
Current smoking (%) 312 (54) 98 (55) 0.863
Hypertension (%) 190 (33) 70 (39) 0.125
Hyperlipidemia (%) 208 (36) 57 (32) 0.369
Previous MI (%) 18 (3) 11 (6) 0.074
Previous PCI (%) 22 (4) 11 (6) 0.206
Heart rate at admission 7218 7319 0.748*
Systolic BT at admission 133 (118–147) 137 (124–157) 0.001†
Diastolic BT at admission 83 (72–94) 90 (75–104) <0.001†
Symptoms to wire, minutes 214 (125–262) 232 (130–290) 0.075†
Peak troponins, ng/L 2390 (893–4930) 4595 (2185–9028) <0.001†
Anterior infarct, verified by ECG (%) 217 (38) 92 (52) 0.001
TIMI flow pre-PCI 0/1 (%) 332 (57) 126 (71) 0.002
TIMI flow post-PCI 3 (%) 562 (97) 167 (94) 0.104
Multiple vessel disease (%) 227 (39) 80 (46) 0.162
Thrombectomy (%) 343 (59) 100 (56) 0.487
Left main (%) 1 (0.2) 0 (0) >0.999
LAD (%) 217 (38) 89 (50) 0.003
LCx (%) 85 (15) 22 (12) 0.464
RCA (%) 274 (47) 66 (37) 0.020
Medication at discharge (%)
ACE inhibitors 178 (31) 90 (51) <0.001
ARB 34 (6) 15 (9) 0.224
b-blockers 536 (93) 161 (91) 0.519
ARA 7 (1) 8 (5) 0.010
Data are presented as meanSD, median (interquartile range) or n (%). ACE indicates angiotensin-converting enzyme; ARA, aldosteron receptor antagonist; ARB, angiotensin II-receptor
blocker; BMI, body mass index; BT, blood pressure; CAD, coronary artery disease; LAD, left anterior descending artery; LCx, left circumﬂex artery; MI, myocardial infarction; PCI, primary
percutaneous intervention; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
Chi-square test was performed unless stated otherwise. *Student t test. †Mann–Whitney U test.
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systolic and diastolic BT, previous MI, symptoms to wire,
anterior infarct location, pre-PCI TIMI ﬂow 0/1, post-PCI TIMI-
ﬂow 3, and multivessel disease (HR, 2.52 [95% CI, 1.27–5.02;
P=0.008). However, adjusting for acute infarct size in the
multivariable Cox regression analysis, the association
between LVH and the combined endpoint of all-cause
mortality and readmission for heart failure was no longer
signiﬁcant (HR, 1.96 [95% CI, 0.95–4.10; P=0.070).
LV mass indexed by BSA as a continuous variable was
highly signiﬁcant associated with infarct size (r=0.3;
Table 2. Outcomes Evaluated by CMR
n Normal n Hypertrophic P Value
Acute CMR
Acute infarct size (% LV) 558 13 (6–22) 171 22 (15–32) <0.001
Area at risk (% LV) 547 32 (24–38) 170 36 (28–45) <0.001
Acute salvage index 531 0.5 (0.4–0.7) 165 0.4 (0.2–0.5) <0.001
Presence of MVO 558 251 (45%) 172 113 (66%) <0.001*
Acute LVEF 579 53 (46–59) 178 45 (39–52) <0.001
Acute ESV index 579 37 (30–45) 178 51 (42–62) <0.001
Acute EDV index 579 80 (70–89) 178 95 (85–104) <0.001
Eccentric LVH 81 46%
Concentric LVH 97 54%
Final CMR
Final infarct size (% LV) 490 9% (3–17) 157 15% (10–21) <0.001
Final salvage index 466 0.7 (0.5–0.9) 150 0.6 (0.5–0.7) <0.001
Final LVEF 492 61 (55–65) 157 53 (47–60) <0.001
Final ESV index 492 32 (26–39) 157 45 (35–58) <0.001
Final EDV index 492 80 (72–91) 157 97 (86–109) <0.001
Final LV mass index 492 57 (50–63) 157 74 (68–82) <0.001
Data are presented as median (interquartile range) or n (%). CMR indicates cardiac magnetic resonance; EDV, end-diastolic volume; ESV, end-systolic volume; LV, left ventricle; LVEF, left
ventricular ejection fraction; LVH, left ventricular hypertrophy; MVO, microvascular obstruction.
Mann–Whitney U test was performed unless stated otherwise. *Chi-square test.
Figure 2. Acute infarct size (% of left ventricular mass) plotted
against myocardial area at risk (% of left ventricular mass). The line
for the LVH group lies signiﬁcantly above the line for the
normotrophic group (P<0.001). In both groups, the infarct size
correlates with the area at risk r=0.68 and 0.49, P<0.001. LV
indicates left ventricle; LVH, left ventricular hypertrophy.
Figure 3. Final infarct size (% of left ventricular mass) plotted
against myocardial area at risk (% of left ventricular mass). The line
for the LVH group lies signiﬁcantly above the line for the
normotrophic group (P<0.001). In both groups, the infarct size
correlates with the area at risk r=0.47 and 0.31, P<0.001. LV
indicates left ventricle; LVH, left ventricular hypertrophy.
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P<0.001), LVEF (r=0.4; P<0.001), myocardial salvage index
(r=0.3; P<0.001), and the combined endpoint of all-cause
mortality and readmission for heart failure (HR, 1.03 [95% CI,
1.01–10.5]; P=0.005).
Stratifying the LVH group according to the calculated sex-
speciﬁc types of hypertrophy, 81 (46%) patients had eccentric
LVH and 97 (54%) concentric LVH. Patients with eccentric
LVH had signiﬁcantly lower acute LVEF, whereas no other
endpoints were signiﬁcantly different between the two groups
(Table 4).
There was no interaction between LVH and treatment
(ischemic postconditioning [P=0.381] and deferred stenting
[P=0.253]) on the effect on infarct size.
Attributed to the difference in previous MI between the
LVH group and the normotrophic group, sensitivity analyses
for patients without previous MI were performed. The
analyses did not change the association between LVH and
CMR parameters, nor did they change the trend between LVH
and the combined endpoint (Tables S1 and S2; Figure S1).
Discussion
In the present study, we observed LVH in 25% of a
consecutive STEMI cohort. These patients had signiﬁcantly
larger infarct size and area at risk, smaller myocardial salvage
index, higher incidence of MVO, and reduced LVEF compared
with normotrophic patients.
The results remained signiﬁcant when adjusting for
potential confounding factors in multivariable models, indi-
cating that LVH is independently associated with increased
infarct size, MVO, and impaired LVEF. Moreover, we showed
an increased risk of all-cause mortality and heart failure in the
presence of LVH, but not when adjusting for infarct size.
These ﬁndings, for the ﬁrst time, demonstrate a causal
relationship between LVH and increased myocardial damage
and that LVH in STEMI patients is related to adverse
prognosis, partly through the mechanism of larger myocardial
damage.
Our ﬁndings are consistent with a previous study in STEMI
patients using CMR to measure LV mass and infarct size.11
However, the ﬁndings by Małek et al were limited by a small
number of patients (n=52), the lack of multivariable analyses
Figure 4. Event rate of the combined endpoint (all-cause mortal-
ity and readmission for heart failure). HR indicates hazard ratio.
Table 4. Comparison of Eccentric and Concentric Left
Ventricular Hypertrophy Evaluated by CMR
n Eccentric n Concentric P Value
Acute CMR
Acute infarct
size (% LV)
77 22 (13–32) 94 22 (16–32) 0.429
Area at risk
(% LV)
78 35 (27–44) 92 36 (29–47) 0.306
Acute salvage
index
75 0.4 (0.3–0.5) 90 0.4 (0.3–0.5) 0.796
Presence of
MVO
77 50 (65%) 95 63 (66%) 0.873*
Acute LVEF 81 43 (37–49) 97 48 (41–54) 0.002
Final CMR
Final infarct
size (% LV)
72 15 (10–25) 85 16 (9–20) 0.413
Final salvage
index
69 0.6 (0.4–0.7) 81 0.6 (0.5–0.7) 0.096
Final LVEF 72 52 (46–59) 85 55 (48–62) 0.090
Data are presented as median (interquartile range) or n (%). CMR indicates cardiac
magnetic resonance; LV, left ventricle; LVEF, left ventricular ejection fraction; MVO,
microvascular obstruction.
Mann–Whitney U test was performed unless stated otherwise. *Chi-square test.
Table 3. Adjusted Association of Left Ventricular
Hypertrophy
Correlation Coefﬁcient P Value
Acute infarct size 0.2 <0.001
Acute salvage index 0.2 <0.001
Acute LVEF 0.2 <0.001
Final infarct size 0.2 <0.001
Final salvage index 0.1 0.006
Final LVEF 0.3 <0.001
Presence of MVO (odds ratio) 1.9 (1.3; 2.8) 0.002*
Left ventricular hypertrophy adjusted for sex, body mass index, hypertension, blood
pressure at admission, previous MI, symptoms to wire, anterior infarct location, pre-PCI
TIMI ﬂow 0/1, post-PCI TIMI-ﬂow 3, and multivessel disease. LVEF indicates left
ventricular ejection fraction; MI, myocardial infarction; MVO, microvascular obstruction;
PCI, primary percutaneous intervention; TIMI, thrombolysis in myocardial infarction.
Multivariable linear regression analysis was performed unless stated otherwise.
*Multivariable logistic regression analysis.
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despite important differences in baseline variables between
LVH and normotrophic patients, and missing measurements
of MVO, area at risk, and salvage index. In contrast to our and
previous observations,6 Małek et al did not report any
difference in LVEF. The importance of measuring area at risk
in addition to infarct size has previously been emphasized
given that area at risk has an impact on infarct size.30 Given
that infarct size, myocardial salvage index, LVEF, LVH, and
MVO are associated with adverse outcome in STEMI
patients,20,22,31–33 ﬁndings in the present study indicate that
the impaired prognosis in patients with acute MI and LVH may
directly be attributed to more-extensive myocardial damage
and smaller salvage.
The differences between the eccentric and concentric LVH
groups regarding LVEF are consistent with a previous study by
Verma et al, who found a signiﬁcantly reduced LVEF in
patients with eccentric LVH.6 They also showed that concen-
tric LVH was associated with a higher risk of adverse
cardiovascular events following a STEMI, even after adjusting
for LVEF, suggesting that the character of LVH carries a great
prognostic value. However, based on our results, a possible
prognostic difference between eccentric and concentric LVH
cannot be attributed by differences in infarct size or
myocardial salvage.
Previous studies have reported very different values for the
upper limit of normal LV mass, with ranges of 89 to 112
(men) and 67 to 89 g/m2 (women). To overcome these
differences, we chose to obtain CMR data from 44 healthy
subjects that match our study cohort. Taken into account that
the papillary muscles were incorporated as part of the LV
cavity, the limits used in the present study are very close to
previously published values.34
The mechanisms for the association between LVH and
larger infarct size are still incompletely understood and may
be numerous. Cardiac hypertrophy decreases capillary
density with as much as 30%,35 resulting in an increased
diffusion distance from capillaries to cardiomyocytes.9,36,37
This exchange may be further hampered by deterioration of
the coronary reserve in hypertrophic hearts1 and an
increase in the extracellular collagen matrix leading to
increased oxygen consumption.5 LVH leads to a shift in
metabolism, which may lead to increased vulnerability to
ischemia.35,38 Finally, ischemia results in interstitial
edema,39 with thickening of the myocardium.40 Thus, a
large area at risk (with subsequent large infarct size)
causes thickening of the myocardial wall, resulting in a
greater LV mass. However, this cannot alone explain the
difference in infarct size between LVH and normotrophic
patients, given that the difference in infarct size remained
statistically signiﬁcant when adjusting for area at risk. Also,
the data in the present study show that the presence of
LVH in STEMI is related to larger infarct size, more-
extensive myocardial damage and poor outcome whatever
the cause for the presence of LVH.
Limitations
First, CMR data on LV mass were obtained after the STEMI
diagnosis. Ischemia results in interstitial edema,39 causing
thickening of the myocardial wall.40 This may pose a risk of
overestimating the number of STEMI patients with LVH in the
present study. However, this is a general challenge regarding
evaluation of LVH in imaging studies on STEMI patients,
regardless of choice of imaging modality. Second, of the 1490
patients considered for CMR in the DANAMI-3 trial at
Rigshospitalet, only 764 underwent CMR. Although reasons
are well described and patients were recruited on a consec-
utive basis, these dropouts may represent a risk of selection
bias, given that the clinical condition is likely to correlate with
infarct size and/or LVEF. Third, area at risk was evaluated
using a T2-weighted CMR technique, which has been validated
against histopathologically deﬁned area at risk.19 Myocardial
salvage assessed by CMR has also been shown to be a
reproducible tool with excellent agreement with single-photon
emission computed tomography and angiography.18,41 How-
ever, T2-weighted images can be technically challenging, with
a sufﬁcient diagnostic quality obtainable in only 88% to 95% of
patients with STEMI.16 Fourth, given the nature of the study,
we did not have continuous data on heart rate and blood
pressure. Furthermore, we did not have information regarding
the duration and severity of hypertension, which would have
been interesting in relation to LVH. Finally, data on medication
at admission were not available.
Conclusions
LVH is independently associated with larger infarct size,
smaller myocardial salvage, a higher incidence of MVO, lower
LVEF, and a signiﬁcantly increased risk of all-cause mortality
and readmission for heart failure in patients with STEMI
treated with primary PCI.
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Table S1. Sensitivity analysis for patients without previous myocardial 
infarction. 
 
 
  
n Normal n Hypertrophic 
  
p value 
    
Acute CMR 
      
      
Acute infarct size (%LV) 541 13 (6-22) 162 22 (15-32)  <0.001 
Area at risk (%LV) 533 32 (24-38) 160 36 (29-45)  <0.001 
Acute salvage index 517 0.5 (0.4-0.7) 156 0.4 (0.3-0.5)  <0.001 
Presence of MVO 541 243 (45%) 163 108 (66%)  <0.001* 
Acute LVEF 561 53 (46-59) 167 45 (39-52)  <0.001 
Acute ESV index 561 37 (30-45) 167 50 (41-61)  <0.001 
Acute EDV index 561 80 (70-89) 167 95 (85-104)  <0.001 
Final CMR  
      
      
Final infarct size (%LV) 476 9 (3-17) 148 15 (9-20)  <0.001 
Final salvage index 456 0.7 (0.5-0.9) 142 0.6 (0.5-0.7)  <0.001 
Final LVEF 479 61 (55-65) 148 53 (47-60)  <0.001 
Final ESV index 479 32 (26-38) 148 45 (36-57)  <0.001 
Final EDV index 479 80 (72-91) 148 100 (87-109)  <0.001 
Final LV mass index 479 57 (50-63) 148 74 (68-82)   <0.001 
       
 
Outcomes evaluated by CMR. 
LV indicates left ventricle; MVO microvascular obstruction; LVEF left ventricular ejection 
fraction; ESV end-systolic volume; EDV end-diastolic volume; LVH left ventricular hypertrophy.  
Data are presented as median (interquartile range) or n (%). 
Mann Whitney U test was performed unless stated otherwise. *Chi-square test. 
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 3 
Table S2. Temporal changes evaluated by CMR. 
  
n Normal n Hypertrophic 
  
p value 
    
        
Mass, grams 492 -8 (-14;0.0) 157 -11 (-17;-5)  <0.001 
LVEDV 492 2 (-7;14) 157 4 (-5;15)  0.305 
LVESV 492 -11 (-26;3) 157 -8 (21;5)  0.215 
LVEF 492 13 (3;24) 157 15 (3;26)  0.307 
Infarct size 451 -33 (-54;-14) 150 -40 (-51;-23)   0.191 
       
 
EDV indicates end-diastolic volume; ESV end-systolic volume; LVEF left ventricular ejection 
fraction; LVH left ventricular hypertrophy.  
Data are shown as relative changes (%) form the first to the second CMR, presented as 
median (interquartile range). 
Mann Whitney U test was performed unless stated otherwise. 
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Figure S1. Cox regression of the combined endpoint of all-cause mortality and readmission for 
heart failure for patients without previous myocardial infarction: 
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